1887

Chapter 54 : Drug Interactions during Anti-Infective Treatments

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Drug Interactions during Anti-Infective Treatments, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815929/9781555812379_Chap54-1.gif /docserver/preview/fulltext/10.1128/9781555815929/9781555812379_Chap54-2.gif

Abstract:

The chapter presents an overview of drug-drug interactions that occur during anti-infective treatments. The solubilization of antifungal azoles, indinavir, delavirdine, or even dapsone requires an acidic pH, so acid suppressants greatly reduce their bioavailability. Di- or trivalent cations lead to the formation of insoluble or weakly soluble chelates with FQ, tetracyclines, rifampin, and ethambutol. Any metabolizable drug that penetrates the enterocyte and gains access to its cytosol will be metabolized by enterocytic CYP, a new stage which may be the subject of an interaction either by competition between substrates or by modification of the metabolic capacities of the enterocyte following coprescription of an enzyme inducer or inhibitor. Pulmonary CYPs are induced by cigarette smoke, a means of eliminating more actively chemicals contained in the smoke. Nowadays, evaluation of potential drug-drug interactions is mandatory for the registration of new drugs by regulatory agencies. The participation of substrate metabolites in drug-drug interactions at both levels, drug transport proteins and CYP enzymes, could also lead to discrepancies. In the vast literature dedicated to metabolic drug interactions, CYP3A4 has received the greatest attention. In the vast literature dedicated to metabolic drug interactions, CYP3A4 has received the greatest attention. The question of a fixed margin versus a varying margin in noninferiority trials has been addressed statistically for anti-infective treatments, taking into account the variable underlying clinical success rate of the reference treatment.

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54

Key Concept Ranking

Bacterial Proteins
0.665047
Chemicals
0.5719195
Alkaloids
0.5541068
ATP-Binding Cassette Superfamily
0.5131579
0.665047
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4
Figure 4

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 5
Figure 5

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815929.ch54
1. Aiba T,, Takehara Y,, Okuno M,, Hashimoto Y, 2003, Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats, Pharm Res, 20, 745748.
2. Benet LZ,, Cummins CL,, Lau YY,, Wu CY, 2003, New discoveries in enzymes and transporters (OATP, P-gp) that affect systemic exposure: what does it mean for biopharmaceutics and clinical pharmacology? Bio-International 2003: Towards harmonisation in bioavailability and bioequivalence, London, UK, 8–10 October 2003.
3. Cazeneuve C,, Pons G,, Rey E,, Treluyer JM,, Cresteil T,, Thiroux G,, d’Athis P,, Oliver G, 1994, Biotransformation of caffeine in human liver microsomes from foetus, neonates, infants and adults, Br J Clin Pharmacol, 37, 405412.
4. Christians U,, Jacobsen W,, Benet LZ,, Lampen A, 2002, Mechanisms of clinically relevant drug interactions associated with tacrolimus, Clin Pharmacokinet, 41, 813851.
5. Drescher S,, Glaeser H,, Mürdter T,, Hitzl M,, Eichelbaum M,, Fromm MF, 2003, P-glycoprotein mediated intestinal and biliary digoxin transport in humans, Clin Pharmacol Ther, 73, 223231.
6. George J,, Murray M,, Byth K,, Farrell GC, 1995, Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease, Hepatology, 21, 120128.
7. Gomez D,, Hebert M,, Benet LZ, 1994, The effect of ketoconazole on the intestinal metabolism and bioavailability of cyclosporin, Clin Pharmacol Ther, 55, 209.
8. Gorski JC,, Vannaprasaht S,, Hamman MA,, Ambrosius WT,, Bruce MA,, Haehner-Daniels B,, Hall SD, 2003, The effect of age, sex and rifampicin administration on intestinal and hepatic cytochrome P450 3A activity, Clin Pharmacol Ther, 74, 275287.
9. Greiner B,, Eichelbaum M,, Fritz P,, Kreichgauer HP,, von Richter O,, Zundler J,, Kroemer HK, 1999, The role of intestinal P-glyco-protein in the interaction of digoxin and rifampin, J Clin Invest, 104, 147153.
10. Gurley BJ,, Gardner SJ,, Hubbard MA,, Williams DK,, Gentry WB,, Cui Y,, Ang CYW, 2002, Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans, Clin Pharmacol Ther, 72, 276287.
11. Harris RZ,, Jang GR,, Tsunoda S, 2003, Dietary effects on drug metabolism and transport, Clin Pharmacokinet, 42, 10711088.
12. Hebert MF,, Roberts JP,, Gambertoglio JG,, Benet LZ, 1991, The effects of rifampin on cyclosporin pharmacokinetics, Clin Pharmacol Ther, 49, 129.
13. Hebert MF,, Roberts JP,, Prueksaritanont T,, Benet LZ, 1992, Bioavailability of cyclosporin with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction, Clin Pharmacol Ther, 52, 453457.
14. Huang, S-M, 2003, Drug interactions or lack of drug interactions: what should we care about in terms of BA, BE and PK? Lecture handouts, Bio-International, October 9, 2003, London.
15. Jürgens G,, Christensen HR,, Brosen K,, Sonne J,, Loft S,, Olsen NV, 2002, Acute hypoxia and cytochrome P450 mediated hepatic drug metabolism in humans, Clin Pharmacol Ther, 11, 214220.
16. Laster L,, Johnson M, 2003, Non-inferiority trials, the “at least as good as” criterion, Statist Med, 22, 187200.
17. Lin JH,, Lu AYH, 1998, Inhibition and induction of cytochrome P450 and the clinical implications, Clin Pharmacokinet, 35, 361390.
18. Masuda S,, Uemoto S,, Hashida T,, Inomata Y,, Tanaka K,, Inui KI, 2000, Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient, Clin Pharmacol Ther, 68, 98103.
19. Montay G,, Goueffon Y,, Roquet F, 1984, Absorption, distribution, metabolic fate, and elimination of profloxacin mesylate in mice, rats, dogs, monkeys, and humans, Antimicrob Agents Chemothes, 25, 463472.
20. Nix D,, Gallicano K, 2001, Design and data analysis in drug interaction studies, p 333351, in Piscitelli SC,, Rodvold KA, ed, Drug Interactions in Infectious Diseases, Humana Press, Totowa, N.J.
21. Park GR, 1996, Molecular mechanisms of drug metabolism in the critically ill, Br J Anaesth, 77, 3249.
22. Pascussi JM,, Gerbal-Chaloin S,, Fabre JM,, Maurel P,, Vilarem MJ, 2000, Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes, consequences on cytochrome P450 gene regulation, Mol Pharmacol, 58, 14411450.
23. Rowland M,, Matin SB, 1973, Kinetic of drug-drug interactions, J Pharmacokinet Biopharm, 1, 553567.
24. Schuetz EG,, Furuya KN,, Shuetz JD, 1995, Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms, J Pharmacol Exp Ther, 275, 10111018.
25. Skarke C,, Jarrar M,, Erb K,, Schmidt H,, Geisslinger G,, Lötsch J, 2003, Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine, Clin Pharmacol Ther, 74, 303311.
26. Steinijans VW,, Hartmann M,, Huber R,, Radtke H, 1991, Lack of pharmacokinetic interaction as an equivalence problem, Int J Clin Pharmacol Ther Toxicol, 29, 323328.
27. Thomson PD,, Melmon KL,, Richardson JA,, Cohn K,, Steinbrunn W,, Cudihee R,, Rowland M, 1973, Lidocain pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans, Ann Intern Med, 78, 499508.
28. Vestal RE,, Norris AH,, Tobin JD,, Cohen BH,, Shock NW,, Andres R, 1975, Antipyrine metabolism in man, influence of age, alcohol, caffeine, and smoking, Clin Pharmacol Ther, 18, 425432.
29. Westphal K,, Weinbrenner A,, Giessmann T,, Sturh M,, Franke G,, Zschiesche M,, Oertel R,, Terhaag B,, Kroemer HK,, Siegmund W, 2000, Oral bioavailability of digoxin is enhanced by talinolol, evidence for involvement of intestinal P-glycoprotein, Clin Pharmacol Ther, 68, 612.
30. Whittaker JA, 1970, Genetic control of phenylbutazone metabolism in man, Br Med J, 4, 323328.
31. Yates CR,, Chang C,, Kearbey JD,, Yasuda K,, Schuetz EG,, Miller DD,, Dalton JT,, Swaan PW, 2003, Structural determinants of P-glycoprotein-mediated transport of glucocorticoids, Pharm Res, 20, 17941803.

Tables

Generic image for table
Table 1

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 2

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 3

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 4

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 5

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 6

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 7

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 8

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 9

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 10

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 11

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 12

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 13

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 14

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 15

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 16

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 17

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 18

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 19

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 20

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54
Generic image for table
Table 21

Citation: Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. 2005. Drug Interactions during Anti-Infective Treatments, p 1320-1352. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch54

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error